Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The Wilms' tumor (Wistar-Furth, Columbia University) animal model kills the host in a predictable period of time, associated with widespread metastases (lungs, liver, spleen) regardless of the route of tumor transplantation. Actinomycin D in single or multiple doses has previously been shown to increase survival, reduce the primary tumor weight, as well as the number of metastases in this experimental model. The model thus has close similarity to man. The present report describes a remarkable effect of adriamycin in this animal system. The beneficial results are, however, limited by severe dose-related toxicity. Nevertheless, faced with recurrent or metastatic lesions following prior current conventional clinical therapy, based on the present experimental results, we believe adriamycin treatment should be given serious clinical consideration.
 ...
PMID:Beneficial effects of adriamycin on Wistar-Furth Wilms' tumor. 16 76

An evaluation of single versus multiple therapy utilizing actinomycin D and vincristine to establish optimum therapeutic value on Wilms' tumor was completed in the present study. A Wistar/Furth Wilms' tumor model was treated with four dosage levels of actinomycin D and vincristine in single and multiple courses of treatment immediately after tumor injection. The results observed and analyzed indicated an optimum dose level for each drug and its most effective therapy course. Actinomycin D (at 300 mg/kg) in single or multiple dose was most effective, to an equal degree, in prolonging survival, decreasing the number of metastases, and the weight of the renal primary as well. Vincristine chemotherapy on a low-dose basis was associated chiefly with increased survival only.
 ...
PMID:The effects of chemotherapy on the Wistar-Furth Wilms' Tumor. 17 92

A twenty-three year old patient had simultaneously a left sided seminoma and a right sided malignant teratoma. Two years later a left nephrectomy had to be carried out because of left paraaortic and renal metastases. The patient received radiation therapy and cytostatic therapy with Velbe, Actinomycin D and Prednisone and survived five years with few symptoms. He died with multiple metastases following paraplegia due to a T 4/5 lesion.
 ...
PMID:[Simultaneous occurrence of a malignent teratoma in the left testis and a seminoma in the right testis (author's transl)]. 126 35

Gestational trophoblastic tumor is a term applied to invasive mole, choriocarcinoma, and placental-site trophoblastic tumor. The overall cure rate in the treatment of these gestational trophoblastic tumors now exceeds 90%. This high success rate is the result of (1) inherent sensitivity of trophoblastic tumors to chemotherapy, (2) ability to monitor therapy effectively with the use of human chorionic gonadotropin as a tumor marker, and (3) identification of prognostic factors which allows categorization of patients into high- and low-risk groups for selection of treatment. Virtually all patients with nonmetastatic and low-risk metastatic disease can be cured using single-agent methotrexate or Actinomycin-D chemotherapy. Intensive therapy with combination chemotherapy including etoposide, high-dose methotrexate and Actinomycin D and, where indicated, adjuvant radiotherapy and surgery has resulted in cure rates of 80-90% in patients with high-risk metastatic disease. The factors which are most important in determining response to treatment are: (1) clinicopathologic diagnosis of choriocarcinoma, (2) metastases to sites other than the lung or vagina, (3) number of metastases, (4) previous failed chemotherapy, and (5) WHO score greater than or equal to 8.
 ...
PMID:Gestational trophoblastic tumors. 217 31

The clinical and histopathological features of four cases of clear cell sarcoma of kidney (CCSK) or Bone metastasising renal tumour of childhood (BMRTC) are presented. These cases were identified among 107 primary renal tumours in childhood over a period of 15 years (1973-1987) in the Trivandrum Medical College. Of the 107 cases 96 (89.7 percent) were nephroblastomas and 7 (6.6 percent) were Mesoblastic Nephromas. The incidence of Clear cell sarcoma was 3.7 percent. Abdominal mass and haematuria were the most common clinical features. All the four cases occurred in male children with no predilection for the right or the left kidney. At the time of presentation bone metastasis was not present in any of the four cases. Metastasis to scapula and skull was detected ten months after nephrectomy in one case. Of the four patients three were in stage I disease at the time of diagnosis. All the four cases showed the typical gross morphology and the classic microscopic pattern of Clear Cell sarcoma kidney. The treatment was similar in all the four cases with Surgery followed by radiotherapy and chemotherapy (Vincristine, Adriamycin Actinomycin D and cyclophosphamide). Only one of the four patients is alive and well 12 months after surgery. The literature is reviewed along with a discussion of the gross pathology, histology and histogenesis of clear cell sarcoma of kidney.
 ...
PMID:Clear cell sarcoma of kidney (CCSK)--a clinicopathological study of 4 cases. 259 97

Methotrexate and folinic acid was administered as primary therapy in 185 patients with gestational trophoblastic disease between 1974 and 1984. Methotrexate and folinic acid induced complete remission in 147 (90.2%) of 163 patients with nonmetastatic disease and in 15 (68.2%) of 22 patients with low-risk metastatic disease. Sustained remission was achieved in 132 (81.5%) patients following only one course of chemotherapy. All patients with methotrexate resistance subsequently achieved remission with Actinomycin D or combination chemotherapy. Methotrexate when administered with folinic acid was associated with granulocytopenia, thrombocytopenia, and hepatotoxicity in 11 (5.9%), 3 (1.6%), and 26 (14.1%) patients, respectively. The human chorionic gonadotropin (hCG) regression curve served as a reliable guide for the administration of chemotherapy and enabled the attainment of a high remission rate while limiting chemotherapy exposure. Methotrexate and folinic acid achieves an excellent therapeutic outcome with limited chemotherapy exposure and effectively limits systemic toxicity.
 ...
PMID:Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. 300 16

The term soft tissue sarcoma refers to a large variety of malignant tumors arising in extraskeletal connective tissues that connect, support, and surround discrete anatomic structures. All visceral organs also contain a connective stroma that can undergo malignant transformation. Because of the histological similarities of this group of tumors and their relative rarity, treatment prescriptions for patients that have disseminated disease are most often uniform. In this study, we asked the question whether adding a third drug (cyclophosphamide or actinomycin D) to Adriamycin (Adr [Adria Laboratories, Columbus, OH])-(3,3-dimethyl-1-triazeno)- imidazole-4-carboxamide (DTIC) would improve the response rate and/or survival. A unique feature of this cooperative group clinical trial was the mandatory pathology review of the histological material. All patients of the Southwest Oncology Group between June 1, 1976, and November 17, 1979, who had a biopsy-confirmed diagnosis of a soft tissue sarcoma with convincing clinical or biopsy-documented evidence of metastatic disease were eligible for the study. Patients were randomized to receive (1) Adr, 60 mg/m2 intravenously, day 1, and DTIC, 250 mg/m2 every 3 weeks (104 patients); (2) Adr and DTIC as in (1) and cyclophosphamide, 500 mg/m2, day 1 (112 patients); or (3) Adr and DTIC as in (1) and actinomycin D, 1.2 mg/m2, day 1, (119 patients). There was no statistically significant difference in response rates (33%, 34%, and 24%) (P = .25). Median durations of response were 31 weeks in the Adr-DTIC arm, 26 weeks in the cyclophosphamide-DTIC-Adr arm, and 23 weeks in the Adr-DTIC-Actinomycin D arm (P = .78). Median durations of survival were 37, 42, and 50 weeks, respectively. Again, no statistically significant differences were observed (P = .59). Toxicities from each of these treatment arms were formidable and were equivalent. Prognostic factor analysis showed a prognosis based on bone marrow reserve, sex, and pathology subtype favorable to patients.
 ...
PMID:Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). 329 29

The patient was a 26-year-old male. He was admitted to our hospital with a chief complaint of hemoptysis, cough and left scrotal mass on May 9,1984. Chest X-ray film, LAG and CT revealed multiple lung, lymph node and cerebral metastases. Based on a diagnosis of testicular neoplasm, orchiectomy was performed on May 14,1984. PVB chemotherapy (Cis-diamminedichloro-platinum, Vinblastine and Pepleomycin) was administered. Because he got worse, however, he was treated with another combination chemotherapy, consisting of Methotrexate (MTX, 100 mg/m2 intravenous push (i.v.), 200 mg/m2 12-h infusion, day 1. The dose of MTX was increased with each course. Maximum dose of MTX was 900 mg/m2/day), Vincristine (1.0 mg/m2 i.v. day 1.) Actinomycin D (10 micrograms/kg i.v. days 3.4.5), Cyclophosphamide (600 mg/m2 i.v. day 3.), Adriamycin (30 mg/m2 i.v. day 8.) and Melphalan (6 mg/m2 p.o. day 8.). After 6 courses of this regimen, distant metastases disappeared or were reduced to under one tenth, and complete remission was obtained without severe side effects. The patient was in good health on March 30, 1985.
 ...
PMID:[Case report of choriocarcinoma of testicular origin indicating marked efficacy of a combination chemotherapy of methotrexate, vincristine, actinomycin D, cyclophosphamide, adriamycin and melphalan]. 375 9

Seventy-nine patients with Stage III widely metastatic melanoma were prospectively randomised to a 'no treatment' control group who received on tumour progression DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D 1.5 mg/m2 on Day 1. A total of six courses at 3-week intervals was given. Chemotherapy was only given on progression of disease. The other group received initially Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses and then the same chemotherapy on evidence of progressive disease. Minimum follow up time is 3 yr. The chemotherapy response rate (control 37%, C. parvum 24%) was not statistically different nor was the effect of chemotherapy on the site of individual metastases. Radiotherapy responses for irradiated soft tissue disease again were not significantly different, between the two patient groups. No significant differences in survival (control group median, 4 months, range 1-46; C. parvum median 3 months range 1-35) were observed and only one patient is alive at 35 months. The pattern of relapse was also similar in both groups. Reduction in haematological toxicity consequent on chemotherapy was not observed in the C. parvum-treated patients. No additional benefit was observed when C. parvum was followed by DTIC and Actinomycin D chemotherapy compared with the results from the chemotherapy given alone, although C. parvum on this schedule had minimal toxicity.
 ...
PMID:Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma. 377 45

Metastatic malignant teratoma of the testis is associated with early death for most afflicted patients. Chemotherapy has limited success with this disease. Medroxyprogesterone acetate (MPA) has been known to exert an antitumor effect in cancers of the endometrium, breast and kidney. This paper documents the objective improvement in 3 of 16 patients with metastatic testicular teratoma treated with MPA. The patients were aged 49, 34 and 28 years. 2 of these patients had multiple lung metastases which were unsuccessfully managed by actinomycin D therapy. The 34-year old patient exhibited well-marked tumor regression for several months following MPA therapy. However, his general condition deteriorated with hepatomegaly until death occured. The 49-year old exhibited no sign of tumor occurence and is alive and well 7 years after beginning MPA therapy. The 28-year old patient is currently clinically tumor-free after 2 years of MPA treatment. Actinomycin D will be stopped but MPA will be continued for another 12 months in gradually decreasing doses. The 3 cases demonstrate good response to treatment with MPA. Evidence suggests that progesterone, including MPA, inhibits the release of pituitary gonadotropins causing impairment of spermatogenesis and accessory gland function associated with pronounced degenerative testicular changes. 9 rare cases of spontaneous regression of testicular tumor were documented by Everson and Cale in a literature review covering the period 1900 and 1965. It is unlikely however that the improvement in the 2 cases presented in this report can be attributed to spontaneous regression. In both patients, metastases continued to progress until shortly after MPA treatment was initiated. Prospective multicenter clinical trials should be done to evaluate the therapeutic value of hormones, alone or in combination with chemotherapy and irradiation in the management of malignant testicular teratoma.
 ...
PMID:Possible role of hormones in treatment of metastatic testicular teratomas: tumour regression with medroxyprogesterone acetate. 472 28


1 2 Next >>